One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

T Tandstad, Olof Ståhl, Ulf Håkansson, O Dahl, H S Haugnes, O H Klepp, C W Langberg, A Laurell, J Oldenburg, A Solberg, K Söderström, Eva Cavallin-Ståhl, U Stierner, R Wahlquist, N Wall, G Cohn-Cedermark

Research output: Contribution to journalArticlepeer-review

85 Citations (SciVal)

Abstract

SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.
Original languageEnglish
Pages (from-to)2167-2172
JournalAnnals of Oncology
Volume25
Issue number11
DOIs
Publication statusPublished - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Molecular Reproductive Medicine (013241710), Oncology, MV (013035000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)

Subject classification (UKÄ)

  • Cancer and Oncology

Fingerprint

Dive into the research topics of 'One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.'. Together they form a unique fingerprint.

Cite this